Login
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc.

aldeyra.com

What Do They Do?

Develops experimental medicines for patients with immune-mediated diseases, including dry eye disease, allergic conjunctivitis, and retinal conditions.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

Aldeyra expects to commercialize approved products itself or through pharmaceutical partners. AbbVie has an option for a U.S. collaboration and an exclusive license outside the U.S. for reproxalap.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +51% (Loss)
vs −$7.7M in Q3 FY2025
  • Nov 9, 2026 Aldeyra seeks a new FDA review division for ADX-2191 It withdrew the agreed trial protocol and does not expect to start the planned trial while its request is pending.
  • Sep 29, 2026 Aldeyra plans to appeal the FDA rejection of reproxalap It intends to submit a formal dispute request over the denial of its application for dry eye disease.

RASP pipeline focus The older report highlighted an oral RASP candidate for systemic conditions. The latest describes RASP candidates for systemic and retinal diseases and identifies late-stage candidates for dry eye disease, allergic conjunctivitis, and retinal conditions.

Who Do They Compete With?

Competes with AbbVie, Johnson & Johnson, UCB, Amgen, Bristol-Myers Squibb, Eli Lilly, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support